China SXT Pharmaceuticals (SXTC) Assets (2018 - 2026)

China SXT Pharmaceuticals has reported Assets for 9 years, with the latest figure at $34.8 million in Q1 2026.

• On a quarterly basis, Assets rose 60.43% year-over-year to $34.8 million in Q1 2026; TTM through Mar 2026 was $34.8 million, a 60.43% increase from a year earlier, with the FY2026 full-year figure at $34.8 million, up 60.43% from the prior year.
• Assets was $34.8 million for Q1 2026 at China SXT Pharmaceuticals, up from $26.4 million in the prior quarter.
• The five-year high for Assets was $34.8 million in Q1 2026, with the low at $14.6 million in Q3 2023.
• Average Assets over 5 years is $26.3 million, with a median of $26.4 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Assets tumbled 34.23% in 2023, then soared 112.49% in 2024.
• Over 5 years, Assets stood at $22.2 million in 2022, then sank by 34.23% to $14.6 million in 2023, then jumped by 112.49% to $31.0 million in 2024, then declined by 14.98% to $26.4 million in 2025, then soared by 31.88% to $34.8 million in 2026.
• The last three Assets figures came in at $34.8 million (Q1 2026), $26.4 million (Q3 2025), and $21.7 million (Q1 2025), per Business Quant data.